Not all sufferers with CLL need therapy. Inspite of all latest advancements, the iwCLL even now endorses watchful observation for sufferers with asymptomatic disease.86 This advice is predicated on not less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,10